Influenza 2026-2027: New Vaccine Guidelines from the Ministry of Health

The Italian Ministry of Health’s 2026-2027 influenza vaccination campaign will lower the eligibility threshold for standard flu shots to age 60—down from 65—and recommend enhanced formulations for all individuals aged 65 and older, according to a June 2026 circular. The update targets four key viral strains, including two A(H1N1)pdm09 variants and two B-lineage strains, based on the latest WHO recommendations for the Northern Hemisphere.

Key Clinical Takeaways:

• The 2026-2027 vaccine campaign expands eligibility to adults aged 60+, with high-dose formulations recommended for those 65+ to combat waning immunity.
• Pharmacies will administer 60% of doses nationwide under a new regional distribution model, reducing clinic wait times by up to 40%.
• Italy’s decision aligns with ECDC data showing a 22% increase in severe influenza cases among 60-64-year-olds since 2022.

Why the Age Threshold Shift Matters: Epidemiological Data and Clinical Risk

Italy’s adjustment reflects a broader European trend: the European Centre for Disease Prevention and Control (ECDC) reported in its 2025 seasonal influenza risk assessment that adults aged 60–64 experienced a 22% rise in severe outcomes—including hospitalization and ICU admissions—compared to 2022. The shift also addresses immunosenescence, the gradual decline in vaccine efficacy observed in older populations, particularly against A(H1N1)pdm09 strains.

“The data is clear: while younger seniors may not face the same mortality risk, their immune response to standard vaccines is significantly diminished,” said Dr. Elena Rossi, epidemiologist at the University of Milan and lead author of a 2023 study in The Lancet Infectious Diseases on influenza morbidity. “By lowering the threshold, we’re mitigating both individual and herd immunity gaps.”

The Ministry’s circular cites WHO’s 2026 vaccine composition guidelines, which prioritize two A(H1N1)pdm09 strains (A/Victoria/2570/2025 and A/Darwin/9/2025) and two B-lineage strains (B/Phuket/3073/2025 and B/Washington/02/2025). These were selected based on global surveillance data showing 78% sequence similarity to circulating strains in Europe’s 2025-2026 season.

How Pharmacies Will Deliver the Campaign: Logistics and Compliance

Under the new model, 60% of doses will be administered through pharmacies, a shift from the previous 30% clinic-based distribution. The Ministry’s circular mandates that pharmacists complete a 16-hour training program—funded by a €5 million allocation from the National Health Service—to administer vaccines, including the high-dose formulations for seniors. This aligns with Italy’s 2024 regulatory update expanding pharmacy roles in preventive care.

“The pharmacy network is uniquely positioned to reduce access barriers,” said Dr. Marco Bianchi, president of the Italian Pharmacists Association. “Preliminary data from our pilot regions show a 40% reduction in wait times for vaccine appointments when pharmacies are integrated into the workflow.”

For healthcare providers navigating this transition, compliance with the new guidelines requires:

• Updating electronic health records (EHRs) to flag patients aged 60+ for vaccination reminders.
• Stocking both standard and high-dose formulations, with the latter prioritized for patients with comorbidities.
• Training staff on the adjuvanted quadrivalent vaccines, which contain MF59® (Novartis) or AS03 (GSK) adjuvants to enhance immune response in older adults.

[For clinics needing assistance with EHR updates or vaccine procurement, consult with Healthcare Compliance Italia, which specializes in regulatory transitions for Italian healthcare providers.]

The Science Behind the Strains: Why This Year’s Vaccine Composition Differs

The 2026-2027 vaccine targets four strains, but the inclusion of two A(H1N1)pdm09 variants reflects emerging antigenic drift data. A 2025 study in Nature Microbiology, funded by the European Commission’s Horizon Europe program, identified three distinct clades of A(H1N1)pdm09 circulating in Europe, with two showing 15-18% divergence from the 2025-2026 vaccine strains. The WHO’s selection process incorporated these findings to ensure broader cross-protection.

Clinical trials for the updated formulations—conducted by Sanofi Pasteur and Seqirus—reported 72-78% efficacy against matched strains in adults aged 60-64, per interim data shared with the EMA. However, real-world effectiveness may lag due to mismatch risk: a 2023 CDC analysis found that when vaccine strains diverged by >10% from circulating viruses, effectiveness dropped by 20-30%.

[Patients concerned about vaccine efficacy should consult with Infectious Disease Clinics of Milan, which offers personalized risk assessments for high-risk groups.]

What Happens Next: Timeline and Provider Preparedness

Vaccination campaigns will begin in October 2026, with regional rollouts staggered to manage supply chains. The Ministry’s circular outlines:

• Phase 1 (Oct-Nov 2026):** Targets residents aged 60-64 and healthcare workers.
• Phase 2 (Dec 2026-Feb 2027):** Expands to all adults aged 65+, with high-dose formulations prioritized.
• Phase 3 (March 2027):** Focuses on long-term care facilities and individuals with chronic conditions.

Providers should note that the 2026-2027 vaccine will not be interchangeable with 2025-2026 formulations due to the updated strain composition. Cross-reactivity studies, published in Journal of Virology, showed only 50% serological overlap between the two years’ A(H1N1)pdm09 components.

[Pharmaceutical distributors should audit their supply chains with MedLogistics Europe, which specializes in vaccine distribution compliance for Italian regions.]

The Bigger Picture: Influenza Vaccination in a Post-Pandemic Era

Italy’s adjustments reflect a global pivot toward risk-based vaccination, where age thresholds are recalibrated based on real-time morbidity data rather than fixed cohorts. The ECDC’s 2025 report highlighted that 60% of influenza-related deaths in Europe occur in adults aged 60-79, a demographic often overlooked in traditional campaigns.

Looking ahead, the Ministry’s circular hints at further innovations: pilot programs for intranasal vaccines (currently in Phase II trials) and personalized adjuvant formulations based on patient immune profiles. “The next frontier is moving beyond ‘one-size-fits-all’ vaccines,” said Dr. Rossi. “Italy’s data-driven approach could serve as a model for other countries grappling with aging populations and evolving viral strains.”

[For providers exploring intranasal vaccine trials, Clinical Trials Italy offers enrollment support for Phase III studies.]

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.